nominally significantP = 0.010
A gain in ISG15 was nominally significantly associated with better recurrence-free survival (RFS) [HR (95% CI):0.40 (0.2–0.80), P = 0.010], disease-specific survival (DSS) [HR:0.30 (0.13–0.71), P = 0.006] and overall survival (OS) [HR:0.31 (0.14–0.69), P = 0.004], but not after correction for multiple testing.